Financial statement as at 31 December 2018

Udgivet den 06-02-2019  |  kl. 05:57  |  

STRONG RESULTS; SIGNIFICANT INCREASE IN CASH RETURNS TO SHAREHOLDERS

Highlights

Organic net revenue growth of 6.5%; reported net revenue growth of 3.0% to DKK 62,503m.Price/mix improvement of 2%.Total organic volume growth of 4.8%; reported growth of 5.3%. Tuborg volume growth of 10%, Carlsberg +5%, Grimbergen +14% and 1664 Blanc +49%.Craft & speciality volume growth of 26%; alcohol-free brew volumes in Western Europe +33%. Funding the Journey as a specific programme successfully concluded with total benefits of around DKK 3bn.Organic operating profit growth of 11.0%; reported growth of 5.1% to DKK 9,329m. Gross margin improvement of 20bp and operating margin improvement of 30bp to 14.9%. Adjusted net profit growth of 9% to DKK 5,359m.Free cash flow of DKK 6,156m.Net interest-bearing debt/EBITDA of 1.29x.ROIC improvement of 120bp to 8.1%. Excluding goodwill, improvement of 520bp to 20.9%.The Supervisory Board will propose a 13% increase in dividend to DKK 18.0 per share, equal to an adjusted payout ratio of 51%.The Company will today initiate a 12-month share buy-back programme of DKK 4.5bn (see page 18 in the attached announcement).

2019 Earnings expectations

Mid-single-digit percentage organic growth in operating profit.A DKK translation impact on operating profit of around zero, based on the spot rates as at 5 February.


CEO Cees 't Hart says: "We delivered a strong set of results for 2018. In line with our ambitions for SAIL'22, we accelerated top-line growth, improved margins, delivered a strong cash flow and reduced debt even further. At the same time, we invested significant resources in our brands and activities, and we continue to target top-line growth and profit improvement in the coming years.
"We're pleased that, on the back of the strong results, the Supervisory Board will recommend a 13% increase in dividend to DKK 18 per share and initiate a share buy-back programme of DKK 4.5bn, leading to cash returns to shareholders for the year of DKK 7.2bn."


Contacts

Investor Relations:         
Peter Kondrup    +45 2219 1221     
Iben Steiness     +45 3327 1232

Media Relations:            
Kasper Elbjørn   +45 4179 1216       
Anders Bering    +45 4179 1217

The Carlsberg Group will present the results at a conference call today at 9.00 am CET (8.00 am GMT). Dial-in information and slide deck are available beforehand on www.carlsberggroup.com.

Attachments

01_UK-06022019_FY2018 Financial Statement Quarterly_financial_data_Carlsberg_Group

\Hugin

Udgivet af: NPinvestordk

Seneste nyheder

17:49 Europa/lukning: Danske fedmeaktier blødte og trak Europa i rødt
17:19 Fredagens obligationer: Renter faldt efter amerikanske inflationstal
17:18 Novo banket i bund efter skuffende data - aktionærerne tabte omkring 690 mia. kr.
17:06 Fredagens aktier: Øretæver til Novo Nordisk og Zealand Pharma giver solid C25-nedtur
15:46 USA/åbning: Eli Lilly vinder på Novos kollaps mens inflationsdata skærer lidt af dykket
15:17 Jeudan har milliarder klar til opkøb: "Øget optimisme kan give flere transaktioner i 2025"
15:15 Novo/Jyske Bank: Kursreaktion virker som overreaktion
14:29 USA/tendens: Eli Lilly vinder på Novos kollaps mens frygt for nedlukning varsler rød start
13:33 Korr: Udsalg af Novo-aktier presser kronen
13:24 Udsalg af Novo-aktier presser kronen
12:29 Sydbank-analytiker: Voldsomt kursfald afspejler skuffelsen over Cagrisema-data
12:25 Europa/aktier: Danske fedmeaktier bløder og trækker Europa i rødt
12:22 Novo smadres på børsen efter skuffende fedmestudie - aktien taber 770 mia. kr.
12:11 Novos styrtdyk trækker C25-indekset ned i sit fjerdestørste fald nogensinde
12:09 Gubra og Zealand Pharma trækkes med ned af negativt nyt til Novo Nordisk
12:05 Novo lever ikke op til egne forventninger i vigtigt studie - aktien mister 900 mia kr -NY2
11:56 Novo lever ikke op til egne forventninger i kursfølsomt studie - aktien mister 700 mia kr
11:48 Aktier/middag: Zealand Pharma bankes tocifret ned efter FDA-afvisning og trækker C25 ned
11:28 Obligationer/middag: Små renteudsving før inflationsnyt fra USA
10:49 Jefferies ser kurslussing til Zealand Pharma som købsmulighed